Respira Therapeutics, Inc.

📍 Palo Alto, United States🗓 Founded 2010👥 9 employees💰 Last funded Sep 2010
Biotechnology Research🌐 respiratherapeutics.com
Website LinkedIn
Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira’s lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Respira Therapeutics, Inc.?
Respira Therapeutics, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Respira Therapeutics, Inc. last raise funding?
The most recent investment in Respira Therapeutics, Inc. recorded on gritt.io was in September 2010.
When was Respira Therapeutics, Inc. founded?
Respira Therapeutics, Inc. was founded in 2010.
What industry is Respira Therapeutics, Inc. in?
Respira Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Respira Therapeutics, Inc. based?
Respira Therapeutics, Inc. is headquartered in Palo Alto, United States.